ADMA BIOLOGICS, INC. (NASDAQ:ADMA) Files An 8-K Entry into a Material Definitive AgreementItem 1.01
On November 9, 2017, ADMA Biologics, Inc., a Delaware corporation (the “Company”), announced that it has priced an underwritten public offering (the “Offering”) to which the Company issued and sold an aggregate of 16,976,744 shares of its common stock, par value $0.0001 per share (the “Common Stock”), at a purchase price of $2.15 per share, for total gross proceeds of approximately $36.5 million, before deducting estimated fees and expenses payable by the Company in connection with the Offering. to the terms of the Underwriting Agreement, dated November 8, 2017 (the “Underwriting Agreement”), entered into by and between the Company and Raymond James & Associates, Inc., as the representative of the several underwriters named therein (collectively, the “Underwriters”), the Company granted to the Underwriters a 30-day option to purchase up to an additional 2,546,511 shares of Common Stock to cover over-allotments, if any. The initial closing is expected to take place on November 13, 2017, subject to the satisfaction of customary closing conditions. The shares of Common Stock offered by the Company in this transaction were registered under the Company’s registration statement on Form S-1, as amended (File No.333-220910), which was declared effective by the Securities and Exchange Commission on November 8, 2017.
Raymond James & Associates, Inc. is acting as the sole book-running manager and representative of the Underwriters for the Offering. Ladenburg Thalmann & Co. Inc. is acting as the lead manager of the Offering.
The Company will pay (i) the Underwriters an aggregate fee equal to 6.0% of the gross proceeds of the Offering to the public equal to approximately $1.4 million, (ii) the Underwriters an aggregate fee equal to 4.0% of the gross proceeds of the Offering to certain of the Company’s current stockholders named in the Underwriting Agreement equal to approximately $0.5 million, and (iii) estimated expenses of the Offering equal to approximately $125,000.
A copy of each of the Underwriting Agreement and the related press release of the Company, dated November9, 2017, are filed herewith as Exhibits 1.1 and 99.1, respectively, and are incorporated herein by reference. The foregoing description of the Offering by the Company and the documents related thereto is qualified in its entirety by reference to such exhibits.
(d) Exhibits
ADMA BIOLOGICS, INC. ExhibitEX-1.1 2 e617459_ex1-1.htm 16,…To view the full exhibit click here
About ADMA BIOLOGICS, INC. (NASDAQ:ADMA)
ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.
